{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:14:02Z","timestamp":1794276842900,"version":"4.9.0"},"reference-count":172,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The use of therapeutic drug monitoring (TDM) to guide treatment with long-acting injectable (LAI) antipsychotics, which are increasingly prescribed, remains a matter of debate. The aim of this review was to provide a practical framework for the integration of TDM when switching from an oral formulation to the LAI counterpart, and in maintenance treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The authors critically reviewed 3 types of data: (1) positron emission tomography data evaluating dopamine (D2\/D3) receptor occupancy related to antipsychotic concentrations in serum or plasma; D2\/D3 receptors are embraced as target sites in the brain for antipsychotic efficacy and tolerability, (2) pharmacokinetic studies evaluating the switch from oral to LAI antipsychotics, and (3) pharmacokinetic data for LAI formulations. Based on these data, indications for TDM and therapeutic reference ranges were considered for LAI antipsychotics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Antipsychotic concentrations in blood exhibited interindividual variability not only under oral but also under LAI formulations because these concentrations are affected by demographic characteristics such as age and sex, genetic peculiarities, and clinical variables, including comedications and comorbidities. Reported data combined with positron emission tomography evidence indicated a trend toward lower concentrations under LAI administration than under oral medications. However, the available evidence is insufficient to recommend LAI-specific therapeutic reference ranges.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Although TDM evidence for newer LAI formulations is limited, this review suggests the use of TDM when switching an antipsychotic from oral to its LAI formulation. The application of TDM practice is more accurate for dose selection than the use of dose equivalents as it accounts more precisely for individual characteristics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000830","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T07:37:20Z","timestamp":1605857840000},"page":"79-102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":50,"title":["Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs"],"prefix":"10.1097","volume":"43","author":[{"given":"Georgios","family":"Schoretsanitis","sequence":"first","affiliation":[{"name":"The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Baumann","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Lausanne, Prilly-Lausanne, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Conca","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Central Hospital, Sanitary Agency of South Tyrol, Bolzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Dietmaier","sequence":"additional","affiliation":[{"name":"Psychiatric Hospital, Klinikum am Weissenhof, Weinsberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Giupponi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Central Hospital, Sanitary Agency of South Tyrol, Bolzano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Hahn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University of Frankfurt, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenia","family":"Hart","sequence":"additional","affiliation":[{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Havemann-Reinecke","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychosomatics, University of G\u00f6ttingen, G\u00f6ttingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Hefner","sequence":"additional","affiliation":[{"name":"Forensic Psychiatric Hospital, Vitos Klinik, Eichberg, Eltville, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Kuzin","sequence":"additional","affiliation":[{"name":"Psychiatric and Psychotherapeutic Private Clinic Clienia Schl\u00f6ssli, Academic Teaching Hospital of the University of Zurich, Oetwil am See, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainald","family":"M\u00f6ssner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, University of T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Piacentino","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Central Hospital, Sanitary Agency of South Tyrol, Bolzano, Italy;"},{"name":"Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, National Institute on Drug Abuse Intramural Research Program, National Institute on Alcohol Abuse and Alcoholism, Division of Intramural Clinical and Biological Research, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Steimer","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Zernig","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Medical University of Innsbruck, Innsbruck, Austria;"},{"name":"Private Practice for Psychotherapy and Court-Certified Witness, Hall in Tirol, Austria; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.schres.2016.09.014","article-title":"Antipsychotic long-acting injections: a community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation","volume":"178","author":"Verdoux","year":"2016","journal-title":"Schizophr Res."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamapsychiatry.2017.4711","article-title":"Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder","volume":"75","author":"Lahteenvuo","year":"2018","journal-title":"JAMA Psychiatry."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/eip.12826","article-title":"Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder","volume":"14","author":"Abdel-Baki","year":"2020","journal-title":"Early Interv Psychiatry."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/08039488.2019.1632381","article-title":"Cannabis use correlates with aggressive behavior and long-acting injectable antipsychotic treatment in Asian patients with schizophrenia","volume":"73","author":"Park","year":"2019","journal-title":"Nord J Psychiatry."},{"key":"R5-20250603","first-page":"112479","article-title":"Suicide attempts in people with schizophrenia before and after participating in an intensive case managed community program: a 20-year follow-up","author":"Diaz-Fernandez","year":"2019","journal-title":"Psychiatry Res."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus Guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr Res."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12991-019-0254-2","article-title":"Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia","volume":"19","author":"Kim","year":"2020","journal-title":"Ann Gen Psychiatry."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/1471-244X-13-340","article-title":"Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness","volume":"13","author":"Llorca","year":"2013","journal-title":"BMC Psychiatry."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"18","DOI":"10.9740\/mhc.2019.01.018","article-title":"Evaluation of oral antipsychotic supplementation of select second-generation long-acting injectable antipsychotics in an acute-care psychiatric setting","volume":"9","author":"Alastanos","year":"2019","journal-title":"Ment Health Clin."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"95","DOI":"10.9740\/mhc.2017.05.095","article-title":"Dosing strategies for switching from oral risperidone to paliperidone palmitate: effects on clinical outcomes","volume":"7","author":"Hsia","year":"2017","journal-title":"Ment Health Clin."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/14740338.2016.1155553","article-title":"Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists","volume":"15","author":"Fagiolini","year":"2016","journal-title":"Expert Opin Drug Saf."},{"key":"R13-20250603","first-page":"829","article-title":"Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data","volume":"25","author":"Samtani","year":"2011","journal-title":"CNS Drugs."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1185\/03007990903482772","article-title":"Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia","volume":"26","author":"Gopal","year":"2010","journal-title":"Curr Med Res Opin."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/YIC.0b013e32834093d1","article-title":"Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching","volume":"26","author":"Detke","year":"2011","journal-title":"Int Clin Psychopharmacol."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/17512433.2017.1345623","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone","volume":"10","author":"Schoretsanitis","year":"2017","journal-title":"Expert Rev Clin Pharmacol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/17512433.2018.1549489","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone","volume":"11","author":"Schoretsanitis","year":"2018","journal-title":"Expert Rev Clin Pharmacol."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/JCP.0000000000000961","article-title":"Age impacts olanzapine exposure differently during use of oral versus long-acting injectable formulations: an observational study including 8,288 patients","volume":"38","author":"Tveito","year":"2018","journal-title":"J Clin Psychopharmacol."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00228-019-02768-0","article-title":"Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status","volume":"76","author":"Tveito","year":"2020","journal-title":"Eur J Clin Pharmacol."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"e0201371","DOI":"10.1371\/journal.pone.0201371","article-title":"Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy","volume":"13","author":"Ostuzzi","year":"2018","journal-title":"PLoS One."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","article-title":"Dopamine targeting drugs for the treatment of schizophrenia: past, present and future","volume":"16","author":"Li","year":"2016","journal-title":"Curr Top Med Chem."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/NDT.S3072","article-title":"Long-acting injectable antipsychotics: focus on olanzapine pamoate","volume":"6","author":"Lindenmayer","year":"2010","journal-title":"Neuropsychiatr Dis Treat."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12272-013-0105-7","article-title":"Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia","volume":"36","author":"Park","year":"2013","journal-title":"Arch Pharm Res."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/mp500070m","article-title":"Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics","volume":"11","author":"Remenar","year":"2014","journal-title":"Mol Pharm."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/03602537808993786","article-title":"Pharmacokinetic studies on flupenthixol decanoate, a depot neuroleptic of the thioxanthene group","volume":"8","author":"Jorgensen","year":"1978","journal-title":"Drug Metab Rev."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1600-0447.1983.tb09718.x","article-title":"Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology","volume":"67","author":"Wistedt","year":"1983","journal-title":"Acta Psychiatr Scand."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1192\/bjp.169.5.618","article-title":"Large variations of plasma levels during maintenance treatment with depot neuroleptics","volume":"169","author":"Tuninger","year":"1996","journal-title":"Br J Psychiatry."},{"key":"R29-20250603","first-page":"CD001470","article-title":"Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders","volume":"2","author":"Quraishi","year":"2000","journal-title":"Cochrane Database Syst Rev."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00491981","article-title":"Comparison of serum levels after intramuscular injections of 2% and 10% cis(Z)-flupentixol decanoate in Viscoleo to schizophrenic patients","volume":"65","author":"Stauning","year":"1979","journal-title":"Psychopharmacology (Berl)."},{"key":"R31-20250603","first-page":"38","article-title":"Electroconvulsive therapy and prolactin release: relation to treatment response in melancholia","volume":"1","author":"Abrams","year":"1985","journal-title":"Convuls Ther."},{"key":"R32-20250603","first-page":"CD001718","article-title":"Depot fluspirilene for schizophrenia","volume":"1","author":"Abhijnhan","year":"2007","journal-title":"Cochrane Database Syst Rev."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s002280050679","article-title":"In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol","volume":"55","author":"Pan","year":"1999","journal-title":"Eur J Clin Pharmacol."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1021\/jm00076a022","article-title":"Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors","volume":"36","author":"Jaen","year":"1993","journal-title":"J Med Chem."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0006-8993(99)02354-9","article-title":"Cytochrome P-450 activities in human and rat brain microsomes","volume":"855","author":"Voirol","year":"2000","journal-title":"Brain Res."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/00003495-200363050-00004","article-title":"Intramuscular preparations of antipsychotics: uses and relevance in clinical practice","volume":"63","author":"Altamura","year":"2003","journal-title":"Drugs."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0447.1993.tb03329.x","article-title":"A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis","volume":"87","author":"Baastrup","year":"1993","journal-title":"Acta Psychiatr Scand."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0278-5846(89)90005-5","article-title":"Pharmacokinetics of three different injectable zuclopenthixol preparations","volume":"13","author":"Aaes-J\u00f8rgensen","year":"1989","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF00174677","article-title":"Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate","volume":"94","author":"Viala","year":"1988","journal-title":"Psychopharmacology (Berl)."},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/BF02412115","article-title":"Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate","volume":"89","author":"Szukalski","year":"1986","journal-title":"Psychopharmacology (Berl)."},{"key":"R41-20250603","first-page":"CD000525","article-title":"Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses","volume":"4","author":"Jayakody","year":"2012","journal-title":"Cochrane Database Syst Rev."},{"key":"R42-20250603","first-page":"CD001164","article-title":"Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses","volume":"2","author":"Coutinho","year":"1992","journal-title":"Cochrane Database Syst Rev."},{"key":"R43-20250603","first-page":"17","article-title":"Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents","volume":"9","author":"Sheehan","year":"2012","journal-title":"Innov Clin Neurosci."},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40263-013-0083-9","article-title":"Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective","volume":"27","author":"Rauch","year":"2013","journal-title":"CNS Drugs."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40263-018-0508-6","article-title":"Long-acting injectable second-generation antipsychotics: an update and comparison between agents","volume":"32","author":"Jann","year":"2018","journal-title":"CNS Drugs."},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.schres.2013.06.041","article-title":"Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study","volume":"150","author":"Mallikaarjun","year":"2013","journal-title":"Schizophr Res."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0000000000000691","article-title":"Aripiprazole Lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia","volume":"37","author":"Hard","year":"2017","journal-title":"J Clin Psychopharmacol."},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.schres.2014.09.021","article-title":"Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia","volume":"159","author":"Turncliff","year":"2014","journal-title":"Schizophr Res."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/1039856217751986","article-title":"Paliperidone palmitate three-month depot formulation: a helpful innovation with practical pitfalls","volume":"26","author":"Hope","year":"2018","journal-title":"Australas Psychiatry."},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2147\/NDT.S5463","article-title":"Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia","volume":"6","author":"Di Lorenzo","year":"2010","journal-title":"Neuropsychiatr Dis Treat."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1211\/0022357043969","article-title":"Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates","volume":"56","author":"El Ela","year":"2004","journal-title":"J Pharm Pharmacol."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1586\/ern.12.137","article-title":"A review of paliperidone palmitate","volume":"12","author":"Chue","year":"2012","journal-title":"Expert Rev Neurother."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/14737175.2013.811984","article-title":"New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia","volume":"13","author":"Citrome","year":"2013","journal-title":"Expert Rev Neurother."},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2165\/00126839-200506030-00001","article-title":"Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system","volume":"6","author":"Ereshefsky","year":"2005","journal-title":"Drugs R D."},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00023210-200418020-00005","article-title":"Long-acting risperidone: a review of its use in schizophrenia","volume":"18","author":"Harrison","year":"2004","journal-title":"CNS Drugs."},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/jcph.141","article-title":"A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone","volume":"53","author":"Gomeni","year":"2013","journal-title":"J Clin Pharmacol."},{"key":"R57-20250603","article-title":"Single quantum dot tracking unravels agonist effects on the dopamine receptor dynamics","author":"Kovtun","year":"2020","journal-title":"Biochemistry."},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psyneuen.2018.11.023","article-title":"Gene expression signature in brain regions exposed to long-term psychosocial stress following acute challenge with cannabinoid drugs","volume":"102","author":"Tomas-Roig","year":"2019","journal-title":"Psychoneuroendocrinology."},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nature09563","article-title":"The environment and schizophrenia","volume":"468","author":"van Os","year":"2010","journal-title":"Nature."},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","article-title":"Mechanism of new antipsychotic medications: occupancy is not just antagonism","volume":"60","author":"Grunder","year":"2003","journal-title":"Arch Gen Psychiatry."},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus Guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/JCP.0000000000000065","article-title":"Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications","volume":"34","author":"Uchida","year":"2014","journal-title":"J Clin Psychopharmacol."},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.euroneuro.2005.10.006","article-title":"Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable","volume":"16","author":"Medori","year":"2006","journal-title":"Eur Neuropsychopharmacol."},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0006-3223(91)90132-6","article-title":"High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients","volume":"29","author":"Coppens","year":"1991","journal-title":"Biol Psychiatry."},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry."},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s002130050420","article-title":"A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients","volume":"133","author":"Farde","year":"1997","journal-title":"Psychopharmacology (Berl)."},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/archpsyc.1997.01830220079011","article-title":"Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings","volume":"54","author":"Nyberg","year":"1997","journal-title":"Arch Gen Psychiatry."},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/ajp.152.2.173","article-title":"D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate","volume":"152","author":"Nyberg","year":"1995","journal-title":"Am J Psychiatry."},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00004850-199709000-00002","article-title":"Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate","volume":"12","author":"Regenthal","year":"1997","journal-title":"Int Clin Psychopharmacol."},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002139900333","article-title":"Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels","volume":"149","author":"Fitzgerald","year":"2000","journal-title":"Psychopharmacology (Berl)."},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s002130050277","article-title":"The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study","volume":"131","author":"Kapur","year":"1997","journal-title":"Psychopharmacology (Berl)."},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"19cs13169","DOI":"10.4088\/JCP.19cs13169","article-title":"Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft Fur Neuropsychopharmakologie und Pharmakopsychiatrie","volume":"81","author":"Schoretsanitis","year":"2020","journal-title":"J Clin Psychiatry."},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/BF00589893","article-title":"Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels","volume":"99","author":"Baron","year":"1989","journal-title":"Psychopharmacology (Berl)."},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S1461145798001229","article-title":"D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients","volume":"1","author":"Nyberg","year":"1998","journal-title":"Int J Neuropsychopharmacol."},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF00210831","article-title":"PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride","volume":"92","author":"Farde","year":"1987","journal-title":"Psychopharmacology (Berl)."},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00213-004-1802-1","article-title":"A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration","volume":"175","author":"Talvik","year":"2004","journal-title":"Psychopharmacology (Berl)."},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00004850-199511000-00003","article-title":"Central D2 receptor occupancy and effects of zuclopenthixol acetate in humans","volume":"10","author":"Nyberg","year":"1995","journal-title":"Int Clin Psychopharmacol."},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1017\/S1461145704004924","article-title":"Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia","volume":"8","author":"Gefvert","year":"2005","journal-title":"Int J Neuropsychopharmacol."},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.npp.1301409","article-title":"D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia","volume":"33","author":"Mamo","year":"2008","journal-title":"Neuropsychopharmacology."},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/appi.ajp.163.3.396","article-title":"A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone","volume":"163","author":"Remington","year":"2006","journal-title":"Am J Psychiatry."},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.4088\/JCP.v69n0811","article-title":"Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia","volume":"69","author":"Uchida","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-12-26","article-title":"A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia","volume":"12","author":"Coppola","year":"2012","journal-title":"BMC Psychiatry."},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am J Psychiatry."},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4088\/JCP.11m07074","article-title":"Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial","volume":"73","author":"Covell","year":"2012","journal-title":"J Clin Psychiatry."},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200505000-00001","article-title":"Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies","volume":"20","author":"Moller","year":"2005","journal-title":"Int Clin Psychopharmacol."},{"key":"R86-20250603","first-page":"298","article-title":"A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy","volume":"57","author":"Wei","year":"1996","journal-title":"J Clin Psychiatry."},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/0278-5846(95)00230-8","article-title":"Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid","volume":"19","author":"Aymard","year":"1995","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"R88-20250603","first-page":"1155","article-title":"A loading-dose strategy for converting from oral to depot haloperidol","volume":"44","author":"Ereshefsky","year":"1993","journal-title":"Hosp Community Psychiatry."},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0278-5846(95)00293-6","article-title":"Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate","volume":"20","author":"Jann","year":"1996","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"R90-20250603","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1600-0447.1980.tb00621.x","article-title":"Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. An open multicenter study","volume":"62","author":"Deberdt","year":"1980","journal-title":"Acta Psychiatr Scand."},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/j.1552-4604.1987.tb02175.x","article-title":"The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients","volume":"27","author":"Nayak","year":"1987","journal-title":"J Clin Pharmacol."},{"issue":"1 suppl","key":"R92-20250603","doi-asserted-by":"crossref","first-page":"30S","DOI":"10.1097\/00004714-198602001-00006","article-title":"A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence","volume":"6","author":"Vasavan Nair","year":"1986","journal-title":"J Clin Psychopharmacol."},{"issue":"1 suppl","key":"R93-20250603","first-page":"20S","article-title":"Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate","volume":"6","author":"Kane","year":"1986","journal-title":"J Clin Psychopharmacol."},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1600-0447.1982.tb00850.x","article-title":"Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients","volume":"65","author":"Viukari","year":"1982","journal-title":"Acta Psychiatr Scand."},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1192\/bjp.148.5.560","article-title":"Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration","volume":"148","author":"De Cuyper","year":"1986","journal-title":"Br J Psychiatry."},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000468580","article-title":"Pharmacokinetics of haloperidol decanoate. A 2-year follow-up","volume":"17","author":"Reyntigens","year":"1982","journal-title":"Int Pharmacopsychiatry."},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-2007-1017373","article-title":"Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention","volume":"18","author":"Kissling","year":"1985","journal-title":"Pharmacopsychiatry."},{"key":"R98-20250603","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00431778","article-title":"Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia","volume":"87","author":"Chang","year":"1985","journal-title":"Psychopharmacology (Berl)."},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2125.1979.tb01045.x","article-title":"Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate","volume":"8","author":"Wiles","year":"1979","journal-title":"Br J Clin Pharmacol."},{"key":"R100-20250603","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.4088\/JCP.v68n0808","article-title":"Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study","volume":"68","author":"Bai","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2003.11.001","article-title":"Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia","volume":"70","author":"Eerdekens","year":"2004","journal-title":"Schizophr Res."},{"key":"R102-20250603","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.euroneuro.2017.11.009","article-title":"Pharmacokinetics of risperidone in different application forms - comparing long-acting injectable and oral formulations","volume":"28","author":"Schoretsanitis","year":"2018","journal-title":"Eur Neuropsychopharmacol."},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00007691-200502000-00019","article-title":"Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service","volume":"27","author":"Castberg","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R104-20250603","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1744-859X-6-3","article-title":"Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval","volume":"6","author":"Gharabawi","year":"2007","journal-title":"Ann Gen Psychiatry."},{"key":"R105-20250603","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1440-1819.2009.01977.x","article-title":"Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders","volume":"63","author":"Lai","year":"2009","journal-title":"Psychiatry Clin Neurosci."},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0037-1601396","article-title":"Paliperidone long-acting plasma level monitoring and a new method of evaluation of clinical stability","volume":"50","author":"Mauri","year":"2017","journal-title":"Pharmacopsychiatry."},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia","volume":"30","author":"Pandina","year":"2010","journal-title":"J Clin Psychopharmacol."},{"key":"R108-20250603","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","article-title":"Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial","volume":"72","author":"Berwaerts","year":"2015","journal-title":"JAMA Psychiatry."},{"key":"R109-20250603","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/ijnp\/pyw116","article-title":"Aripiprazole once-monthly 400 mg: comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration","volume":"20","author":"Raoufinia","year":"2017","journal-title":"Int J Neuropsychopharmacol."},{"key":"R110-20250603","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF00178510","article-title":"Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate","volume":"88","author":"Marder","year":"1986","journal-title":"Psychopharmacology (Berl)."},{"key":"R111-20250603","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0000000000000913","article-title":"Intraindividual and interindividual variability of olanzapine trough concentrations in patients treated with the long-acting injectable formulation","volume":"38","author":"Baldelli","year":"2018","journal-title":"J Clin Psychopharmacol."},{"key":"R112-20250603","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1055\/s-2007-1014609","article-title":"Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo","volume":"22","author":"Balant","year":"1989","journal-title":"Pharmacopsychiatry."},{"key":"R113-20250603","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/JCP.0000000000000921","article-title":"Pharmacokinetic evaluation of a 1-day treatment initiation option for starting long-acting aripiprazole lauroxil for schizophrenia","volume":"38","author":"Hard","year":"2018","journal-title":"J Clin Psychopharmacol."},{"key":"R114-20250603","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1007\/s00213-019-05311-2","article-title":"Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia-a systematic review of the literature","volume":"236","author":"Bailey","year":"2019","journal-title":"Psychopharmacology (Berl)."},{"key":"R115-20250603","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1192\/bjp.146.4.439","article-title":"Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings","volume":"146","author":"Turbott","year":"1985","journal-title":"Br J Psychiatry."},{"key":"R116-20250603","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/BF00432123","article-title":"Steady-state serum concentrations after cis (Z)-flupentixol decanoate in viscoleo","volume":"80","author":"Saikia","year":"1983","journal-title":"Psychopharmacology (Berl)."},{"key":"R117-20250603","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-198704000-00008","article-title":"The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime","volume":"2","author":"Cookson","year":"1987","journal-title":"Int Clin Psychopharmacol."},{"key":"R118-20250603","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/BF02316862","article-title":"Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose","volume":"105","author":"Kistrup","year":"1991","journal-title":"Psychopharmacology (Berl)."},{"key":"R119-20250603","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00433729","article-title":"A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency","volume":"78","author":"Wistedt","year":"1982","journal-title":"Psychopharmacology (Berl)."},{"key":"R120-20250603","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1192\/bjp.142.6.579","article-title":"Serum concentration of depot neuroleptics in tardive dyskinesia","volume":"142","author":"Fairbairn","year":"1983","journal-title":"Br J Psychiatry."},{"key":"R121-20250603","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00004714-198506000-00004","article-title":"Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate","volume":"5","author":"Brown","year":"1985","journal-title":"J Clin Psychopharmacol."},{"key":"R122-20250603","first-page":"245","article-title":"Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view","volume":"49","author":"Boza","year":"1988","journal-title":"J Clin Psychiatry."},{"key":"R123-20250603","first-page":"425","article-title":"Significant greater loss of medication from the injection site when fluphenazine (Prolixin) decanoate was injected intramuscularly as contrasted with subcutaneously","volume":"48","author":"Gelenberg","year":"1987","journal-title":"J Clin Psychiatry."},{"key":"R124-20250603","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2710.1995.tb00629.x","article-title":"Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate","volume":"20","author":"Miller","year":"1995","journal-title":"J Clin Pharm Ther."},{"key":"R125-20250603","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00004714-198512000-00004","article-title":"Plasma levels of neuroleptic in patients receiving depot fluphenazine","volume":"5","author":"Cohen","year":"1985","journal-title":"J Clin Psychopharmacol."},{"key":"R126-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0920-9964(00)00184-5","article-title":"Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate","volume":"53","author":"Marder","year":"2002","journal-title":"Schizophr Res."},{"key":"R127-20250603","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00004850-198710000-00002","article-title":"Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals","volume":"2","author":"Norman","year":"1987","journal-title":"Int Clin Psychopharmacol."},{"key":"R128-20250603","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0006-3223(85)90063-0","article-title":"Effects of smoking on fluphenazine clearance in psychiatric inpatients","volume":"20","author":"Ereshefsky","year":"1985","journal-title":"Biol Psychiatry."},{"key":"R129-20250603","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0920-9964(88)90025-4","article-title":"Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia","volume":"1","author":"Glazer","year":"1988","journal-title":"Schizophr Res."},{"key":"R130-20250603","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF02246213","article-title":"A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia","volume":"117","author":"Goff","year":"1995","journal-title":"Psychopharmacology (Berl)."},{"key":"R131-20250603","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00007691-199910000-00001","article-title":"Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients","volume":"21","author":"Pan","year":"1999","journal-title":"Ther Drug Monit."},{"key":"R132-20250603","first-page":"129","article-title":"Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration","volume":"32","author":"Sychev","year":"2017","journal-title":"Drug Metab Pers Ther."},{"key":"R133-20250603","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF02801983","article-title":"Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol","volume":"106","author":"Eyles","year":"1992","journal-title":"Psychopharmacology (Berl)."},{"key":"R134-20250603","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/BF02245440","article-title":"A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients","volume":"114","author":"Dencker","year":"1994","journal-title":"Psychopharmacology (Berl)."},{"key":"R135-20250603","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/FTD.0b013e31811f394d","article-title":"Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome","volume":"29","author":"Panagiotidis","year":"2007","journal-title":"Ther Drug Monit."},{"key":"R136-20250603","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1177\/009127000004001115","article-title":"Effect of chlorpromazine and clozapine on plasma concentrations of haloperidol in a patient with schizophrenia","volume":"40","author":"Allen","year":"2000","journal-title":"J Clin Pharmacol."},{"key":"R137-20250603","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.1979.tb00900.x","article-title":"Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs","volume":"7","author":"Hansen","year":"1979","journal-title":"Br J Clin Pharmacol."},{"key":"R138-20250603","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00426680","article-title":"Perphenazine concentrations in human whole blood. A pilot study during anti-psychotic therapy using different administration forms","volume":"37","author":"Hansen","year":"1974","journal-title":"Psychopharmacologia."},{"key":"R139-20250603","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1365-2125.1976.tb00647.x","article-title":"Clinical pharmacokinetic studies of perphenazine","volume":"3","author":"Eggert Hansen","year":"1976","journal-title":"Br J Clin Pharmacol."},{"key":"R140-20250603","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/FTD.0000000000000585","article-title":"A Compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting","volume":"41","author":"Jonsson","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R141-20250603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1985.tb08536.x","article-title":"Perphenazine decanoate in sesame oil vs. perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical implications","volume":"322","author":"Knudsen","year":"1985","journal-title":"Acta Psychiatr Scand Suppl."},{"key":"R142-20250603","first-page":"2443","article-title":"The effect of serum monitoring on concentration of perphenazine and zuclopenthixole","volume":"155","author":"Thomsen","year":"1993","journal-title":"Ugeskr Laeger."},{"key":"R143-20250603","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cpt.770","article-title":"Treatment with antipsychotics in pregnancy: changes in drug disposition","volume":"103","author":"Westin","year":"2018","journal-title":"Clin Pharmacol Ther."},{"key":"R144-20250603","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00228-015-1965-1","article-title":"Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol","volume":"72","author":"Lisbeth","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"R145-20250603","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/030006059702500104","article-title":"Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients","volume":"25","author":"Syvalahti","year":"1997","journal-title":"J Int Med Res."},{"key":"R146-20250603","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JCP.0000000000001178","article-title":"Serum Aripiprazole concentrations prehemodialysis and posthemodialysis in a schizophrenic patient with chronic renal failure: a case report","volume":"40","author":"De Donatis","year":"2020","journal-title":"J Clin Psychopharmacol."},{"key":"R147-20250603","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/a-1113-7862","article-title":"Paliperidone LAI and aripiprazole LAI plasma level monitoring in the prophylaxis of bipolar disorder type I with manic predominance","volume":"53","author":"Mauri","year":"2020","journal-title":"Pharmacopsychiatry."},{"key":"R148-20250603","first-page":"26","article-title":"A phase-1 study comparing pharmacokinetic and safety profiles of three different dose intervals of aripiprazole lauroxil","volume":"47","author":"Risinger","year":"2017","journal-title":"Psychopharmacol Bull."},{"key":"R149-20250603","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/13651501.2014.1000928","article-title":"\"Long-acting\" olanzapine in maintenance therapy of schizophrenia: a study with plasma levels","volume":"19","author":"Mauri","year":"2015","journal-title":"Int J Psychiatry Clin Pract."},{"key":"R150-20250603","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/JCP.0000000000001126","article-title":"The effect of valproic acid on olanzapine serum concentration: a study including 2791 patients treated with olanzapine tablets or long-acting injections","volume":"39","author":"Tveito","year":"2019","journal-title":"J Clin Psychopharmacol."},{"key":"R151-20250603","doi-asserted-by":"crossref","first-page":"S415","DOI":"10.1093\/schbul\/sby018.1016","article-title":"Can long-acting injectable paliperidone dosing be optimized with plasma levels measurements?","volume":"44","author":"Zipursky","year":"2019","journal-title":"Schizophr Bull."},{"key":"R152-20250603","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0043-122603","article-title":"Can we rely on AGNP therapeutic targets also for LAI antipsychotics?","volume":"51","author":"Baldelli","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"R153-20250603","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/FTD.0000000000000457","article-title":"Serum concentrations of paliperidone after administration of the long-acting injectable formulation","volume":"39","author":"Helland","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R154-20250603","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/JCP.0000000000000714","article-title":"Placental transfer of paliperidone during treatment with a depot formulation","volume":"37","author":"Binns","year":"2017","journal-title":"J Clin Psychopharmacol."},{"key":"R155-20250603","first-page":"57","article-title":"Serum concentration of paliperidone palmitate administered every 3 weeks","volume":"49","author":"Cohen","year":"2019","journal-title":"Psychopharmacol Bull."},{"key":"R156-20250603","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/JCP.0000000000001137","article-title":"Pharmacokinetic-pharmacodynamic characterization of relapse risk for paliperidone palmitate 1-month and 3-month formulations","volume":"39","author":"Russu","year":"2019","journal-title":"J Clin Psychopharmacol."},{"key":"R157-20250603","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1176\/appi.psy.49.3.258","article-title":"A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I","volume":"49","author":"de Leon","year":"2008","journal-title":"Psychosomatics."},{"key":"R158-20250603","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JCP.0b013e3181c17df0","article-title":"Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone","volume":"29","author":"Hendset","year":"2009","journal-title":"J Clin Psychopharmacol."},{"key":"R159-20250603","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e31828f62cd","article-title":"Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects","volume":"33","author":"Choong","year":"2013","journal-title":"J Clin Psychopharmacol."},{"key":"R160-20250603","first-page":"110042","article-title":"ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone","author":"Ganoci","year":"2020","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"R161-20250603","doi-asserted-by":"crossref","first-page":"404","DOI":"10.9740\/mhc.2019.11.404","article-title":"Use of therapeutic drug monitoring of risperidone microspheres long-acting injection in hemodialysis: a case report","volume":"9","author":"Tourtellotte","year":"2019","journal-title":"Ment Health Clin."},{"key":"R162-20250603","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/0091270009350622","article-title":"Inconsistency in risperidone long-acting injection steady-state plasma levels when switching from deltoid to gluteal administration","volume":"50","author":"Elliott","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"R163-20250603","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0091270009355156","article-title":"Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients","volume":"50","author":"Thyssen","year":"2010","journal-title":"J Clin Pharmacol."},{"key":"R164-20250603","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/01.jcp.0000145347.68664.4e","article-title":"High dose of depot risperidone in a nonresponder schizophrenic patient","volume":"24","author":"Albrecht","year":"2004","journal-title":"J Clin Psychopharmacol."},{"key":"R165-20250603","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40262-014-0132-7","article-title":"Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment","volume":"53","author":"Laffont","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R166-20250603","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/bcp.13246","article-title":"Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone","volume":"83","author":"Ivaturi","year":"2017","journal-title":"Br J Clin Pharmacol."},{"key":"R167-20250603","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1017\/S1092852917000840","article-title":"Converting oral to long-acting injectable antipsychotics: a guide for the perplexed","volume":"22","author":"Meyer","year":"2017","journal-title":"CNS Spectr."},{"key":"R168-20250603","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/a-0755-7692","article-title":"Studies of half-lives of long-acting antipsychotics are needed","volume":"52","author":"Schoretsanitis","year":"2019","journal-title":"Pharmacopsychiatry."},{"key":"R169-20250603","article-title":"Plasma levels of long-acting injectable antipsychotics in outpatient care: a retrospective analysis","author":"H\u00fd\u017ea","year":"2020","journal-title":"BMC Psychiatry"},{"key":"R171-20250603","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/BF02244140","article-title":"Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia","volume":"101","author":"Wiles","year":"1990","journal-title":"Psychopharmacology (Berl)."},{"key":"R173-20250603","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF02245407","article-title":"Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment?","volume":"106","author":"Chang","year":"1992","journal-title":"Psychopharmacology (Berl)."},{"key":"R177-20250603","first-page":"40","article-title":"Aripiprazole lauroxil (Aristada): long-acting atypical antipsychotic injection approved for the treatment of patients with schizophrenia","volume":"9","author":"Raedler","year":"2016","journal-title":"Am Health Drug Benefits."},{"key":"R180-20250603","doi-asserted-by":"crossref","first-page":"288","DOI":"10.9758\/cpn.2017.15.3.288","article-title":"Five month-persistent extrapyramidal symptoms following a single injection of paliperidone palmitate: a case report","volume":"15","author":"Jang","year":"2017","journal-title":"Clin Psychopharmacol Neurosci."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:19:08Z","timestamp":1748971148000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":172,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000830","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"2020-08-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}